Drug Search Results
More Filters [+]

Buspirone

Alternative Names: buspirone, buspar, bci-024, bci 024, bci024
Latest Update: 2024-09-27
Latest Update Note: Clinical Trial Update

Product Description

Buspirone is used to treat anxiety disorders or in the short-term treatment of symptoms of anxiety. Buspirone is in a class of medications called anxiolytics. It works by changing the amounts of certain natural substances in the brain. (Sourced from: https://medlineplus.gov/druginfo/meds/a688005.html)

Mechanisms of Action: 5-HT1A Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Bangladesh | Brazil | Canada | Chile | China | Colombia | Czech | Denmark | Dominican Republic | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Malta | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Romania | Russia | Slovakia | Slovenia | South Africa | Sri Lanka | Sweden | Taiwan | Turkey | Ukraine | United Kingdom | United States | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Emotional Brain
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Buspirone

Countries in Clinic: China, Russia

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Dizziness|Generalized anxiety disorder|Myocardial Infarction|Primary Dysautonomias|Vertigo

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BGFN-2022-01

P3

Recruiting

Generalized anxiety disorder

2026-06-30

BUSP-03-03-2021

P3

Completed

Dizziness|Vertigo|Primary Dysautonomias

2022-05-09

48%

2019-002182-35

P3

Active, not recruiting

Unknown

2022-01-10

COOL AMI EU PIVOTAL TRIAL

P3

Active, not recruiting

Myocardial Infarction

None

Recent News Events